Letrozole Monotherapy Falls Short in Ovarian Cancer Clinical Trial

Why It Matters

The findings cement paclitaxel‑carboplatin plus letrozole as the frontline standard for this rare ovarian cancer subtype, while highlighting a possible, less‑toxic alternative for a select surgical subgroup.

Key Takeaways

• Letrozole alone failed non‑inferiority for PFS versus PC/L
• Hazard ratio 1.30 crossed futility threshold of 1.213
• Overall survival remained high: 95% PC/L, 92% letrozole
• PC/L caused significantly more grade 3‑4 toxicities (OR 4.26)
• Subgroup with no residual disease showed smaller PFS gap

Pulse Analysis

Low‑grade serous ovarian carcinoma accounts for a small fraction of ovarian cancers but poses a therapeutic challenge due to its indolent biology and limited responsiveness to conventional chemotherapy. The NRG GY019 trial, the first phase III study to enroll a sizable cohort of this rare disease, compared a hormone‑only strategy—letrozole monotherapy—with the established paclitaxel‑carboplatin regimen followed by letrozole maintenance. By randomizing 450 patients after primary cytoreductive surgery, the study provided robust data on progression‑free survival, overall survival, and safety, offering a much‑needed evidence base for clinicians.

The interim analysis revealed a hazard ratio of 1.30 for progression‑free survival, breaching the pre‑specified non‑inferiority margin and indicating that letrozole alone cannot replace the combination approach for the general patient population. While overall survival remained comparable—95% in the combination arm versus 92% with letrozole—the toxicity profile favored the hormone‑only arm, with the combination therapy showing a four‑fold increase in grade 3‑4 adverse events. These results have immediate implications for treatment guidelines, reinforcing the current recommendation of paclitaxel‑carboplatin plus letrozole as the standard frontline regimen.

Nevertheless, the trial uncovered a nuanced signal: patients who achieved no gross residual disease after surgery exhibited a smaller efficacy gap, with a hazard ratio of 1.15 that did not cross the futility boundary. This raises the prospect of a tailored, less‑toxic approach for a subset of patients, pending further molecular profiling and longer follow‑up. Ongoing correlative studies aim to identify biomarkers that predict benefit from hormone monotherapy, potentially reshaping personalized treatment pathways for low‑grade serous ovarian carcinoma.